{"data":{"type":"company_profile","id":75254,"entity_id":"wefunder:company:75254","attributes":{"canonical_url":"https://wefunder.com/biosmart.research.inc","generated_at":"2026-06-23T02:22:19Z","updated_at":"2026-06-22T05:03:15Z","entity_ids":{"company":"wefunder:company:75254","slug":"wefunder:company_slug:biosmart.research.inc"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-23T02:22:19Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-22T05:03:15Z","as_of":"2026-06-23T02:22:19Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-22T05:03:15Z","as_of":"2026-06-23T02:22:19Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-23T02:22:19Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-23T02:22:19Z","confidence":"medium"}}},"company":{"id":75254,"entity_id":"wefunder:company:75254","slug":"biosmart.research.inc","name":"BioSmart Research, Inc.","tagline":"BioSmart Research: Invest in the future of cannabinoid therapy.","elevator_pitch":"BioSmart Research produces CBD isolate formulas for topical and internal use","story":"Disclaimer: These projections cannot be guaranteedDisclaimer: These projections cannot be guaranteed","location":"Yelm, WA","website":"https://biosmartresearchcbd.com","total_amount_raised":53200,"total_investors":21,"is_funded":true,"is_active":true,"quality_score":3,"related_urls":["https://wefunder.com/biosmart.research.inc","https://biosmartresearchcbd.com"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/75254/xxl_cropped_intro.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/75254/large_cropped_BSR-Square-2.png","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/75254/standard_cropped_intro.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/75254/standard_cropped_intro.jpg","profile_video_url":"https://wefunder.wistia.com/medias/5wwgd78pwn"},"links":{"company_url":"https://biosmartresearchcbd.com"},"highlights":[],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"Launch in 2019 produced $1.7M in sales"},{"index":2,"claim_id":"claim-fact-2","value":"Biosmart produces pain management and anti-anxiety formulas for clinical and retail distribution"},{"index":3,"claim_id":"claim-fact-3","value":"BioSmart has a 3-year technology lead using high-pressure liquid chromatography for isolate extraction"},{"index":4,"claim_id":"claim-fact-4","value":"BioSmart markets through it's own retail dispensaries, healthcare providers, pharmacies, affiliates, and internet sales"},{"index":5,"claim_id":"claim-fact-5","value":"U.S. Market for non-steroidal OTC pain relievers is $21.9 B/yr. US CBD market is $4.7 B/yr."},{"index":6,"claim_id":"claim-fact-6","value":"Clinical dosing levels with CBD isolates produce similar results to OTC pain relievers without the side effects."},{"index":7,"claim_id":"claim-fact-7","value":"BioSmart collaborates with university and clinical researchers and is a member of Choose Wisely, a patient forum"},{"index":8,"claim_id":"claim-fact-8","value":"BioSmart Research represents a responsible approach to improving quality of life and advancing cannabinoid research"}],"team":[{"id":1331835,"entity_id":"wefunder:company_role:1331835","user_entity_id":"wefunder:user:1285846","role":"founder","name":"B Renee Searle","title":"CEO","bio":"Renee has 40 years’ experience as an entrepreneur with 30 patents resulting in $60 MM in product sales. Her fields of research include biotechnology, electronics and cannabinoid research.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/1331835/square_cropped_Founders.jpg?1625499717","profile_url":"https://wefunder.com/b.renee.searle.2","related_urls":["https://wefunder.com/b.renee.searle.2"]}],"featured_investors":[{"id":5443,"entity_id":"wefunder:company_investor_profile:5443","investor_profile_id":995234,"investor_profile_entity_id":"wefunder:investor_profile:995234","subject_entity_id":"wefunder:user:1468760","name":"Eric J Exelbert MD","avatar_url":"http://uploads.wefunder.com/uploads/user/avatar/1468760/medium_cropped_Headshot_with_White_Background.jpg","profile_url":"https://wefunder.com/ericjexelbertmd","investment_total":25000,"investment_info":"Invested $25,000 this round","is_lead_investor":true,"related_urls":["https://wefunder.com/ericjexelbertmd"]}],"investor_memos":[],"tab_counts":{"posts":0,"ask_questions":2,"featured_investors":1,"faq_entries":2},"active_fundraises":[{"id":41077,"entity_id":"wefunder:fundraise:41077","state":"successful","offering_type":"506(b)","funding_type":"note","structure":"ttw","security_type":"debt","currency":"USD","testing_the_waters":true,"min_purchase":100,"max_purchase":9,"funding_target":250000.0},{"id":41076,"entity_id":"wefunder:fundraise:41076","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"convertible_note","security_type":"debt","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":50000.0,"funding_started_at":"2021-06-30T18:08:38Z","funding_closed_at":"2021-12-23T05:01:59Z","auto_close_at":"2021-12-23T04:59:59Z"}],"latest_fundraise":{"id":41077,"entity_id":"wefunder:fundraise:41077","state":"successful","offering_type":"506(b)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null,"terms":{"eb":"$15M","nb":"$20M","txt":"valuation cap"}},"recent_posts":[],"q_and_a":[{"id":167526,"entity_id":"wefunder:comment:167526","question":"What are revenues year-to-date, and did you achieve your goal of being cash-flow positive by the end of summer?","author_name":"Kevin Hardman","votes":0,"created_at":"2021-09-02T23:07:53Z","canonical_url":"https://wefunder.com/biosmart.research.inc#question-167526","answers":[{"id":169313,"entity_id":"wefunder:comment:169313","answer":"Summers not over yet. We got off to a slow start and had to re-hire and train. I expect that we should be cash-flow positive by November.","author_name":"B Renee Searle","votes":0,"created_at":"2021-09-14T21:59:29Z"}]},{"id":158785,"entity_id":"wefunder:comment:158785","question":"What you’re doing is interesting, but I have a few questions: 1) If I understand everything correctly, it looks like the bulk of the nearly $1.9M in revenues earned in 2019 came from equipment sales by Washington State Enterprises, Inc. (WSE). Is WSE still a viable entity, and if so, how much revenue has it generated in 2021? 2) What is the corporate structure of the company and how does WSE fit into it? 3) Does an investment in Biosmart Research also give investors ownership in WSE and any other related companies (e.g., Biosmart Technologies)? 4) It appears that Wen C. Chan has 40% of the voting power and AcePower (which is owned by Wen C. Chan) has 20% of the voting power. Bearing that in mind, would it be correct to say that – with 60% of the voting power - Wen C. Chan controls the company?","author_name":"Kevin Hardman","votes":0,"created_at":"2021-07-19T15:40:45Z","canonical_url":"https://wefunder.com/biosmart.research.inc#question-158785","answers":[{"id":162597,"entity_id":"wefunder:comment:162597","answer":"1. WSE is still a viable entity but we are not currently promoting the equipment sales aggressively. Equipment sales involved engineering and on-site set-up and management which were not possible during the covid lock-down. At that time we had already decided to change direction and promote the formulas which were a result of our research. Covid forced us into lock-down giving us time to set up our own labs and manufacturing facilities to produce our formulas. WSE still has approximately $50,000 in inventory at this time comprised mostly of lab equipment including short-paths, chillers, roto-vaps, and solvent recovery systems. 2. WSE is a wholly owned subsidiary of BioSmart Research, so yes, the investors are vested in WSE also. 3. BioSmart Technologies is an infrared and air purification equipment manufacturer owned by AcePower International. The technology is not related to Cannabinoid Research and is not a part of this offering. Perhaps at some future date diversification and inclusion of this company would be appropriate. 4. AcePower International Marketing is a 20% stakeholder in BioSmart Research. Wen C. Can is the Director and Renee Searle is the General Manager. The funds for the lab were advanced to BioSmart Research by AcePower International Marketing in exchange for the equity. Acepower international Marketing was established in 2012 with offices in Taipei, Taiwan to export parts from Asia to the U.S. to manufacture and sell BioSmart’s products in the U.S. This is an active trading company that is promoting BioSmart Researches Cannabinoid formulas in Asia. Wen C. Chan and Renee Searle were officially married in Taiwan in 2012. The marriage was registered again in 2012 in the U.S. Wen C. Chan is a permanent resident of the U.S. Decisions and control are equally exclusive to Wen and Renee.","author_name":"B Renee Searle","votes":0,"created_at":"2021-08-09T19:49:56Z"}]}],"faq":[{"question":"What you’re doing is interesting, but I have a few questions: 1) If I understand everything correctly, it looks like the bulk of the nearly $1.9M in revenues earned in 2019 came from equipment sales by Washington State Enterprises, Inc. (WSE). Is WSE still a viable entity, and...","answer":"1. WSE is still a viable entity but we are not currently promoting the equipment sales aggressively. Equipment sales involved engineering and on-site set-up and management which were not possible during the covid lock-down. At that time we had already decided to change direction and promote the formulas which were a result of our research. Covid forced us into lock-down giving us time to set up our own labs and manufacturing facilities to produce our formulas. WSE still has approximately $50,..."},{"question":"What are revenues year-to-date, and did you achieve your goal of being cash-flow positive by the end of summer?","answer":"Summers not over yet. We got off to a slow start and had to re-hire and train. I expect that we should be cash-flow positive by November."}]}}}